GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Up 556.9% in December

GT Biopharma, Inc. (NASDAQ:GTBP) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 90,000 shares, an increase of 556.9% from the December 15th total of 13,700 shares. Currently, 4.6% of the company’s shares are short sold. Based on an average daily trading volume, of 365,300 shares, the short-interest ratio is currently 0.2 days.

GT Biopharma Stock Down 9.8 %

GT Biopharma stock traded down $0.26 during midday trading on Monday, reaching $2.39. The company’s stock had a trading volume of 3,841,909 shares, compared to its average volume of 591,458. The business has a 50-day simple moving average of $2.86 and a 200-day simple moving average of $2.57. GT Biopharma has a fifty-two week low of $1.72 and a fifty-two week high of $10.66.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Roth Mkm initiated coverage on GT Biopharma in a research report on Monday, December 2nd. They issued a “buy” rating and a $11.00 target price for the company. Roth Capital raised shares of GT Biopharma to a “strong-buy” rating in a research note on Monday, December 2nd.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.